Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Antiretroviral Drug Researchers, AIDS Advocates Fail to Reach Consensus Over Viread Trials in Developing Countries

May 24, 2005

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Antiretroviral drug researchers, study sponsors and AIDS advocates in a meeting that began last week in Seattle reached some agreement but failed to resolve completely conflicts over the conduct of clinical trials testing whether the antiretroviral drug Viread, which is made by the pharmaceutical company Gilead, can prevent HIV infection among people in developing countries, the Wall Street Journal reports (Chase, Wall Street Journal, 5/24). At issue is whether researchers should provide lifelong antiretroviral treatment -- not just a referral for care -- to people who become HIV-positive while participating in the trials. Protests organized by ACT UP/Paris and other European AIDS organizations demanding such care have led to the cancellation of Viread studies in Cambodia and the suspension of trials in Cameroon. However, researchers say that offering lifelong treatment to volunteers might violate a prohibition on undue inducement to participate in clinical trials. In addition, some AIDS advocates want injection drug users participating in a Viread trial in Thailand to be provided with clean needles. However, the trials are using U.S. funding, and providing clean needles would breach a congressional ban on the practice (Kaiser Daily HIV/AIDS Report, 5/18).

Meeting Outcome
At the meeting -- which was sponsored by the International AIDS Society -- patient advocates met with representatives of the Bill & Melinda Gates Foundation, NIH and CDC. Conferees agreed that trial volunteers should receive more HIV prevention counseling and barrier contraceptives, including female condoms. A report resulting from the meeting said efforts to counsel volunteers were sometimes "ill-informed and inconsistent," according to the Journal. However, the meeting did not resolve the dispute over the provision of lifelong antiretroviral treatment for people who become HIV-positive while participating in the studies. The conferees agreed that "mechanisms" to ensure treatment needed to be established, but they did not agree on the important question of who would pay for treatment, according to the Journal (Wall Street Journal, 5/24).

Back to other news for May 24, 2005

Advertisement

Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More News and Research on HIV Medications for HIV Prevention
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement